Since MEK inhibition inhibits Bregs, we sought to investigate whether B cell anti-tumor immunity is preserved in the setting of MEK inhibition, or whether MEK blocking agents inhibit both anti-tumor and pro-tumor B cell activity. Here, MAP2K7 is linked to neoplasm.